This partnership will enable the partner group to integrate and commercialize the NewGuard safety device, developed by BIOCORP, in the field of pre-filled syringes and more specifically on the heparin segment, an immediate-acting anticoagulant of which it is the 2nd th world player.
∙ Integration and commercialization of NewGuard in the field of pre-filled syringes for the heparin segment
∙ Potential market of more than 150 million units
ISSOIRE, France - ( BUSINESS WIRE ) - Regulatory News:
BioCorp (Paris: ALCOR) (FR0012788065 - ALCOR / PEA-PME eligible) , a French company specializing in the development and manufacture of medical devices and innovative drug delivery systems, today announces the signature of a technical and commercial collaboration with a leading global player in pharmaceuticals 1 .
This partnership will enable the partner group to integrate and commercialize the NewGuard safety device, developed by BIOCORP, in the field of pre-filled syringes and more specifically on the heparin segment, an immediate-acting anticoagulant of which it is the 2nd th world player.
This collaboration, estimated at more than 150 million pieces, represents several tens of millions of euros of revenue for BIOCORP by 2020-2022.
The continuation of the collaboration towards an industrialization phase can be confirmed after a first phase of evaluation of the project taking place over 9 months. This will aim at assessing the durability of the collaboration between the two parties, and will make it possible to specify the conditions of this engagement.
” We are very pleased and honored by the signing of this partnership. This first strategic collaboration with an international giant in the pharmaceutical industry, represents for us a real recognition of our know-how and expertise to provide an additional service to the drug delivered. This is a new strategic step for BIOCORP which, through this agreement, is becoming a key global player in the field of medical safety devices, “ commented Eric Dessertenne, Executive Vice President of BIOCORP .
About NewGuard, the
Newguard Passive Security System is a new generation RNS (Rigid Needle Shield) incorporating a passive security system. Compatible with different formats of pre-filled syringes, it adapts to the filling, sterilization and packaging process without requiring any change for the manufacturer. Easy to use, Newguard brings safety and comfort during and after the injection.
ABOUT BIOCORP
Created in 2004 in Issoire (near Clermont-Ferrand), BIOCORP is a French company, labeled BPI‘Innovative Company’ specializing in the development and manufacture of medical devices and innovative drug delivery systems. With over twenty years of experience, more than 30M units produced each year and 12 patent families, BIOCORP is a recognized player in the sector at the heart of the evolution of delivery systems with solutions that meet the new needs of patients. Today, BIOCORP continues to innovate on medical plastics, its original business, to produce and market traditional devices (alternatives to the aluminum capsule, syringe-bottle reconstitution systems) generating a number of recurring business. Its strong expertise and innovative capacity have also enabled it to develop a range of connected products, including the DataPen, a reusable and communicating pen-injector, connected to a mobile application, and add-ons, which are based on existing dispensing devices that are compatible with most pen-injectors on the market, such as Easylog, the first add-on that transforms insulin delivery devices into connected devices. The company has 48 employees. which attach to existing delivery devices and are compatible with most pen-injectors on the market such as Easylog, the first add-on that transforms insulin delivery devices into connected devices. The company has 48 employees. which attach to existing delivery devices and are compatible with most pen-injectors on the market such as Easylog, the first add-on that transforms insulin delivery devices into connected devices. The company has 48 employees.
BIOCORP has been listed on Euronext Growth Paris since July 2015 (FR0012788065 - ALCOR).
For more information: www.biocorp.fr
Follow us on Twitter @BIOCORPSystems
1 BIOCORP has not been authorized to reveal the identity of the partner at the express request of the said company.
contacts
Biocorp
Jacques Gardette
CEO
investisseurs@biocorp.fr
or
Eric Dessertenne
Managing Director
or
press Relations
ALIZE RP
Caroline Carmagnol / Wendy Rigal
01 44 54 36 66/06 48 82 18 94
biocorp@alizerp.com
